Cantrixil

Cantrixil (TRX-E-002-1), an active enantiomer of TRX-E-002, is a second-generation super-benzopyran (SBP) compound. Cantrixil increases phosphorylated c-Jun levels resulting in caspase-mediated apoptosis in ovarian cancer cells. Cantrixil has potent pan anti-cancer activity against a broad range of cancer phenotypes[1][2].

Product Specifications

CAS Number

[2135511-22-5]

Product Name Alternative

TRX-E-002-1

UNSPSC

12352005

Target

Apoptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cantrixil.html

Purity

99.32

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC1=CC=C([C@H](C2=CC=C(O)C=C2)[C@H](C3=CC(OC)=C(O)C(OC)=C3)CO4)C4=C1C

Molecular Formula

C24H24O6

Molecular Weight

408.44

References & Citations

[1]Muhammad Wasif Saif, et al. Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1) . Cancer Chemother Pharmacol. 2017 Feb;79 (2) :303-314.|[2]Ayesha B Alvero, et al. TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo. Mol Cancer Ther. 2016 Jun;15 (6) :1279-90.